Why is TransMedics stock surging today?

TransMedics stock surged 14.4% in pre-open trading after the medical technology company posted record third-quarter 2026 results that handily beat analyst expectations on every key metric and accompanied the beat with a meaningful raise to its full-year outlook. Total revenue for the quarter came in at $203.0 million, a 41% increase year-over-year, while non-GAAP EPS of $0.51 came in well ahead of the consensus estimate of approximately $0.30. Management raised its full-year 2026 revenue guidance to a range of $764 million to $774 million, above both the prior guidance range and the analyst consensus of approximately $741.8 million.

The earnings strength was reinforced by a flurry of analyst activity. Canaccord Genuity lifted its price target to $120 from $95 while reiterating its Buy rating, and Baird raised its target to $117 from $110 while maintaining an Outperform rating — both citing the breadth of the revenue beat and the improved forward outlook. U.S. Liver and U.S. Heart procedures were highlighted as the primary growth engines for the quarter, with transplant logistics revenue climbing approximately 50% year-over-year. The company also won its first European transplant logistics tender in Italy’s Emilia-Romagna region, which management described as a strategic entry point into the broader European market.

On the macro front, the NASDAQ Composite is up 1.4% today as technology and growth stocks stage a partial recovery following a sharp prior-session selloff driven by concerns over potential AI regulation. The S&P 500 is modestly positive, while the Dow Jones is under pressure. This recovery in growth-oriented names provided a constructive backdrop for a high-growth medical technology company like TransMedics to extend its after-hours gains into the pre-market session.

The combination of a decisive earnings beat, a raised full-year guidance range, and multiple analyst price target upgrades created a powerful, multi-layered catalyst for today’s move. With the stock having declined sharply year-to-date heading into the print, the results appear to have triggered significant short-covering and fresh buying interest, pushing shares toward $78.94 — still well below the 52-week high of $156 but meaningfully above the 52-week low of $60.11 set recently.